MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Boston Scientific Corp.

Suletud

SektorTervishoid

101.15 0.36

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

99.41

Max

101.25

Põhinäitajad

By Trading Economics

Sissetulek

-138M

562M

Müük

352M

4.6B

P/E

Sektori keskmine

82.136

73.239

Aktsiakasum

0.7

Kasumimarginaal

12.322

Töötajad

53,000

EBITDA

-41M

1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+18.85% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-250M

152B

Eelmine avamishind

100.79

Eelmine sulgemishind

101.15

Uudiste sentiment

By Acuity

48%

52%

168 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Boston Scientific Corp. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. märts 2025, 12:35 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5. veebr 2025, 12:23 UTC

Tulu

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

8. jaan 2025, 12:33 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Rest of Bolt Medical for $443 Million

4. nov 2024, 13:01 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Medical-Technology Company Cortex

3. märts 2025, 11:59 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3. märts 2025, 11:58 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3. märts 2025, 11:58 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5. veebr 2025, 21:33 UTC

Tulu

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. veebr 2025, 15:20 UTC

Tulu

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. veebr 2025, 11:39 UTC

Tulu

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5. veebr 2025, 11:39 UTC

Tulu

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5. veebr 2025, 11:38 UTC

Tulu

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5. veebr 2025, 11:38 UTC

Tulu

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q Adj EPS 70c >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q Sales $4.56B >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q EPS 38c >BSX

8. jaan 2025, 12:10 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Sees Deal More Dilutive on GAAP Basis >BSX

8. jaan 2025, 12:09 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Sees Deal Slightly Dilutive to Adj EPS in 2025 >BSX

8. jaan 2025, 12:09 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Pay Up to Another $221M After Certain Regulatory Milestones >BSX

8. jaan 2025, 12:08 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Deal Includes Upfront Payment of About $443M for 74% Stake Not yet Owned >BSX

8. jaan 2025, 12:07 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Buyout to Further Co's Strategy to Address Coronary and Peripheral Disease >BSX

8. jaan 2025, 12:07 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Buyout to Expand Cardiovascular Portfolio With Complementary, Differentiated Calcium Modification Platform >BSX

8. jaan 2025, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Announces Agreement To Acquire Bolt Medical, Inc. >BSX

25. nov 2024, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Announces Agreement To Acquire Intera Oncology(R) Inc. >BSX

15. nov 2024, 13:43 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Closes Acquisition Of Axonics, Inc. >BSX AXNX

Võrdlus sarnastega

Hinnamuutus

Boston Scientific Corp. Prognoos

Hinnasiht

By TipRanks

18.85% tõus

12 kuu keskmine prognoos

Keskmine 120.32 USD  18.85%

Kõrge 135 USD

Madal 108 USD

Põhineb 23 Wall Streeti analüütiku instrumendi Boston Scientific Corp. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

23 ratings

22

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

100.73 / 102.67Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

168 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.